2SE

SEQUANA MEDICAL N.V.

Healthcare · EUR · F

2SE

Price

€0.511

-0.39%

Cap

€40.02M

Earnings

30d Trend

-12.3%

2SE
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

169% annualised over 90 days

BRAIN47 SIGNAL

0
WEAK
Risk Level81
Quality41
Momentum13
Technical47
Fundamentals15

Raw weighted: 30×Macro 0.99 (1%)=30

RISK

81/100
90d Volatility
168.6%High
ATR %
3.9%High daily moves
Max Drawdown (1Y)
-76.3%Volatile

QUALITY

41/100
ROE (avg)
-6.9%Negative
Piotroski F-Score
2/9Weak
Margin Stability
CV 2.4%Very stable
Accruals
-245.3%Cash earnings

MOMENTUM

13/100
12-1M Momentum
-48.2%Strong downtrend
6-1M Momentum
-22.4%Negative
1M Return
-1.0%Stable

TECHNICAL

47/100
RSI (14)
55.3Neutral
Price vs SMA200
-20.2%Bearish trend
MACD
0.00Bearish momentum
Bollinger Band
59%Mid-range
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.259Noisy/choppy

FUNDAMENTALS

15/100
P/S
473.5Expensive

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months44
3-12 months28
1-5+ years24

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate SEQUANA MEDICAL N.V. at 30/100 — a WEAK reading on the Brain47 Signal. The strongest factor is technical at 47/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

-1.0%

3 MONTHS

+1.2%

12 MONTHS

-49.2%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Limited short-term thesis. Technical (47) and Quality (41) are the primary strengths. I note that momentum is the weakest area at 13/100 — this warrants monitoring. Historical volatility is elevated at 169%. I classify this as a speculative position — elevated volatility at 169% and smaller market cap define the opportunity.

speculativeScore: 30/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.